Jul 30, 2020 by Brian Orelli, PhDGilead Sciences' Revenue and Earnings Slip in Second QuarterIt wasn't pretty, but look for an improvement in the second half of this year.
Jul 29, 2020 by Brian Orelli, PhDRoche's Rheumatoid Arthritis Drug Fails to Help COVID-19 Patients (Again)Actemra fails another clinical trial, but there are still two ongoing late-stage studies.
Jul 28, 2020 by Brian Orelli, PhDHumanigen Stock Up 13% After NIH Picks Its Drug for a COVID-19 StudyThe study will measure how the combination of lenzilumab and remdesivir fares compared to remdesivir alone.
Jul 27, 2020 by Brian Orelli, PhDEmergent BioSolutions Triples Its Coronavirus-Vaccine Manufacturing Contract With AstraZenecaThere could be an even larger contract coming if the vaccine to prevent COVID-19 is successful.
Jul 17, 2020 by Brian Orelli, PhDHere's Why Evolent Health Jumped Higher TodayThe company is making lemonade out of the lemons that Kentucky's Medicaid program handed it.
Jul 16, 2020 by Brian Orelli, PhDHere's Why AC Immune Jumped Higher TodayInvestors are excited about the company advancing its Alzheimer's disease vaccine, but caution is warranted.
Jul 16, 2020 by Brian Orelli, PhDJohnson & Johnson's Revenue and Earnings Slipped in the Second QuarterThe pandemic took some wind out of the healthcare conglomerate's sails, but its results weren't as bad as expected.
Jul 15, 2020 by Brian Orelli, PhDFull Results From Moderna's Coronavirus Vaccine Study Will Take 2 Years, at LeastFortunately, the full data may not be required to get the vaccine on the market.
Jul 14, 2020 by Brian Orelli, PhDEverything You Need to Know About Moderna's ValuationShares of the coronavirus vaccine maker are up 276% this year.
Jul 10, 2020 by Brian Orelli, PhDGilead's Remdesivir Cuts Risk of COVID-19 Death by 62% -- MaybeThere's a major caveat to the claim.
Jul 10, 2020 by Brian Orelli, PhDPfizer and BioNTech's Coronavirus Vaccine Ready for Regulatory Submission in December, Maybe EarlierThe companies' CEOs give different timelines on a potential submission.
Jul 8, 2020 by Brian Orelli, PhDTherapeutics Acquisition Corp. Jumps 22% in IPO DebutThe special purpose acquisition company is sponsored by RA Capital Management.
Jul 8, 2020 by Brian Orelli, PhDModerna Completes Enrollment in Phase 2 COVID-19 Vaccine Study; Phase 3 Start on TrackInvestors continue to wait for detailed phase 1 data for the coronavirus vaccine.
Jul 8, 2020 by Brian Orelli, PhDHere's Why Pfizer Fell 14% in JuneThe pharma giant missed an opportunity for growth as breast cancer treatment Ibrance failed a key clinical trial.
Jul 8, 2020 by Brian Orelli, PhDHere's Why CRISPR Therapeutics Shares Jumped 13.8% in JuneA pair of scientific presentations have investors more confident in the biotech's pipeline.
Jul 7, 2020 by Brian Orelli, PhDBioCryst Pharmaceuticals Jumped Higher Today; Here's Why Investors May Be WrongThere might be a simple explanation for why the company doubled the expected enrollment in its COVID-19 clinical trial.
Jul 6, 2020 by Brian Orelli, PhDHere's Why Sorrento Therapeutics Skyrocketed 24% Higher in JuneThe biotech is making progress with its COVID-19 products.
Jul 2, 2020 by Brian Orelli, PhDHere's Why BioLife Solutions Jumped Higher TodayIt doesn't look like the COVID-19 pandemic had much effect on sales of the company's bioproduction products for cell and gene therapies.
Jul 1, 2020 by Brian Orelli, PhDPfizer and BioNTech Post Positive Trial Data for Their COVID-19 VaccinePatients developed antibodies to the coronavirus in the phase 1 clinical trial, but the vaccine also produced side effects.
